A Director at Clovis Oncology (CLVS) is Selling Shares


Today, a Director at Clovis Oncology (CLVS), James C. Blair, sold shares of CLVS for $474K.

See today’s analyst top recommended stocks >>

Based on Clovis Oncology’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $30.35 million and GAAP net loss of $99.26 million. In comparison, last year the company earned revenue of $17.04 million and had a GAAP net loss of $51.88 million. Currently, Clovis Oncology has an average volume of 1.5M. The Company has a Price to Book ratio of 9.8913.

Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $31.40, reflecting a 14.3% upside.

The insider sentiment on Clovis Oncology has been negative according to 37 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts